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ABSTRACT 
Background: Current evidence suggests that older people and people with underlying comorbidities 
are at increased risk of severe disease and death following hospitalisation with COVID-19. As 
comorbidity increases with age, it is necessary to understand the age-adjusted relationship between 
comorbidity and COVID-19 outcomes, in order to enhance planning capabilities and our understanding 
of COVID-19.  
Methods: We conducted a rapid, comprehensive review of the literature up to 10 April 2020, to assess 
the international empirical evidence on the association between comorbidities and severe or critical care 
outcomes of COVID-19, after accounting for age, among hospitalised patients with COVID-19. 
Results: After screening 579 studies, we identified seven studies eligible for inclusion and these were 
synthesised narratively. All were from China. The emerging evidence base mostly indicates that after 
adjustment for age (and in some cases other potential confounders), obesity, hypertension, diabetes 
mellitus, chronic obstructive airways disease (COPD), and cancer are all associated with worse 
outcomes. The largest study, using a large nationwide sample of COVID-19 patients in China, found 
that those with multiple comorbidities had more than twice the risk of a severe outcome or death 
compared with patients with no comorbidities, after adjusting for age and smoking (HR=2.59, 95% CI 
1.61, 4.17). 
Conclusions: This review summarises for clinicians, policymakers, and academics the most robust 
evidence to date on this topic, to inform the management of patients and control measures for tackling 
the pandemic. Given the intersection of comorbidity with ethnicity and social disadvantage, these 
findings also have important implications for health inequalities. As the pandemic develops, further 
research should confirm these trends in other settings outside China and explore mechanisms by which 
various underlying health conditions increase risk of severe COVID-19.  
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BACKGROUND 
Since first emerging at the end of 2019, the novel coronavirus SARS-CoV-2 is known to have infected 
at least 3.7 million people and caused more than 260,000 deaths globally (1). As of the end of April 
2020, the pandemic remains uncontained in many parts of the world, and countries recovering from a 
first wave of infections are concerned about subsequent waves before an effective vaccine is available. 
To minimise mortality and morbidity in the meantime, and to direct scarce resources most appropriately, 
a better understanding of the risk factors for progression to severe coronavirus disease 2019 (COVID-
19) and death is urgently needed.  
Emerging reports and descriptive analyses from China and Italy suggested that people with underlying 
comorbidities were overrepresented in symptomatic hospitalised cases, and were at increased risk of 
progression to severe disease and death (2-4). Other countries have reported similar findings as the 
pandemic has spread (5, 6). Given that the prevalence of comorbidity increases with age, it is unclear 
whether and how comorbidity independently influences risk of COVID-19 progression. Many early 
studies into the epidemiology of COVID-19 reported baseline comorbidities of hospitalised patients but 
not age-adjusted estimates of excess risk associated with comorbidities. Understanding the relationship 
between comorbidity and COVID-19 outcomes would enhance planning capabilities and potentially 
our understanding of COVID-19 pathogenesis, management, and prognosis.  
To provide timely evidence, we conducted a rapid but comprehensive review addressing the following 
question: What is the international empirical evidence on the association between comorbidities and 
severe or critical care outcomes of COVID-19, after accounting for age, among hospitalised patients 
with COVID-19? Outcomes of interest were: 
a. Admission to intensive care unit (ICU)  
b. Invasive or non-invasive ventilation 
c. Deaths in hospital  
d. Progression to severe disease 
 
METHODS 
Inclusion and exclusion criteria 
The inclusion and exclusion criteria focused on comparison of age-adjusted estimates of association 
between any comorbidity and in-hospital COVID-19 outcomes (severity, critical care or death) (Table 
1), in peer-reviewed studies, pre-prints from repositories such as medRxiv, and several grey literature 
sources of official statistics and evidence summaries, published by 10 April 2020, in English, from any 
country. We defined comorbidity as a pre-existing health condition present at admission to hospital 
with COVID-19, including obesity but excluding health-related behaviours such as smoking. 
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Table 1. Review inclusion and exclusion criteria: What is the association between comorbidities 
and age-adjusted severe or critical care outcomes in hospital patients with COVID-19? 
 INCLUDE EXCLUDE 
Population Adult COVID-19 hospital patients.  
 
Studies with 10 or more patients. 
 
 
Not population-based sample (e.g. 
samples in clinical trials, samples from 
cruise ships, familial clusters; studies with 
less than 10 patients).  
 
Non-COVID-19 patients (e.g. other 
pneumonia cases). 
 
Community cases not receiving care in 
hospitals, including general population 
estimates of the spread of COVID-19. 
 
Studies focusing solely on infants and 
children (not part of a study including 
adults). 
Interventions/outcomes Relative risk, hazard ratio, odds ratio 
associated with comorbidity (pre-existing 
condition) status on admission, of: 
i. admission to intensive care 
ii. invasive or non-invasive ventilation 
iii. progression to severe disease 
iv. death in hospital 
v. composite indicators of i-iv,  
 
for any reported comorbidity (chronic 
illness, pre-existing condition). 
 
Other treatments inside and outside 
critical care departments, e.g. rates of 
patients receiving oxygen 
supplementation. 
Comparison Patients with and without any comorbidity 
at admission to hospital. Comorbidity was 
defined as pre-existing health conditions 
present at admission to hospital with 
COVID-19, including obesity.  
Comparisons within a sample of patients 
who all have a comorbidity (e.g. studies of 
cancer patients only). Comparisons 
between groups of people based on their 
health-related behaviours (e.g. smoking), 
ethnicity or socioeconomic circumstances.  
Study design All primary quantitative empirical 
observational studies reporting 
multivariable regression models (with 
adjustment for age) or age-specific 
association between comorbidity and 
outcome. 
Qualitative studies. 
 
Intervention studies (e.g. clinical trials of 
new treatments for COVID-19). 
 
Projections or estimations of potential 
outcomes. 
 
Non-empirical studies, including editorials, 
opinions, or discussion pieces.  
 
Studies that do not report comorbidity-
related risk estimates 
 
Review-level evidence 
Publication characteristics 
 INCLUDE EXCLUDE 
Publication stage, type Pre-prints, peer-reviewed publications, 
grey literature on empirical evidence (e.g. 
official statistics). 
Not applicable. 
Language English language publications. Non-English language publications (not 
available for full text). 
Date Studies with data from December 2019 and 
published by 10th April, 2020. 
Studies before December 2019. 
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Search strategy and study identification  
The search strategy had four arms (Figure 1) involving electronic database searches and a wide range 
of ‘supplementary’ systematic review search methods.  
First, we screened the studies already identified in the initial search from our companion review on 
COVID-19 critical care outcomes (Pennington et al. unpublished, which screened 2665 items), for any 
that met our narrower search criteria. 
Second, all studies identified in that companion review underwent Web of Science and Google Scholar 
forward-citation searches, with initial filtering for key terms relating to comorbidity and age. 
Third, we searched a range of additional sources including the World Health Organization (WHO); 
communicable disease centres of the USA, Europe, and China; and several COVID-19-specific 
evidence resources online (shown as “outside sources” in the flow chart, Figure 1; see Appendix 1 for 
details). 
Fourth, in a new search of the MEDLINE full-text database (as title and abstract often omit age-
adjustment), we modified the companion review’s search strategy to identify additional analytical 
(rather than descriptive) studies that were focused on comorbidities specifically or reported 
multivariable analysis of risk factors for severe or critical care outcomes of COVID-19 (see Appendix 
1 for full search terms).  
Screening 
In each of Arms 1-3, title-abstract screening was followed by full-text screening by a single reviewer. 
In Arm 4, title-abstract screening by one reviewer excluded any studies clearly not meeting the inclusion 
criteria, followed by independent title-abstract screening of the remaining studies by two reviewers in 
EPPI Reviewer-4 systematic review management software (7).  
Duplicates remaining after the screening of the additional MEDLINE search were excluded at this stage. 
To produce this report quickly, three reviewers shared searching and screening tasks, rather than 
repeating tasks independently, except where otherwise stated. Two reviewers independently screened 
the full text of the final set of studies screened as potentially eligible.  
Data extraction 
One reviewer extracted any age-adjusted estimate of excess risk (relative risk, hazard or odds ratio) 
associated with any comorbidity (variously defined) for the outcomes of interest, recording them in an 
Airtable Pro database. A second reviewer checked each extraction for accuracy and missing data. Where 
studies reported multiple estimates adjusted for different sets of covariates (e.g. age alone, age plus sex, 
other comorbidities, smoking status), all relevant age-estimates were extracted. One reviewer then 
selected the most appropriate one for reporting in the review, checked by others. No assessment was 
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made at this stage of the comparability of estimates or the appropriateness of the covariate selection in 
each study’s adjusted regression models. Instead, such assessment was made in the synthesis of results. 
Synthesis 
Evidence was synthesised narratively (8, 9) and study quality was assessed informally. Limited 
replication of studies for any individual comorbidity and the inclusion of non-peer-reviewed pre-
prints meant that meta-analysis was not viable.  
RESULTS 
A total of 579 studies were screened (Figure 1), of which seven studies were included in the review (10-
16) (Appendix 2). 
 
Figure 1. Flow chart of progression of studies through the review of age-adjusted associations 
between comorbidity and outcomes of COVID-19 
 
No studies were identified in the screening of 27 studies identified from the companion review. Forward 
citation searches of those 27 led to the screening of 382 studies and identified three primary studies for 
potential inclusion though (10, 15, 17). One of these was then excluded because it was not clear if 
selection into the study was limited to hospitalised cases (17). Of 49 studies screened from outside 
sources, several reviews were identified that led to the identification of five primary studies of potential 
relevance, of which four were assessed as eligible for inclusion (11, 13, 14, 16). A Centers for Disease 
Control and Prevention (CDC) publication (18) was excluded because it analysed a composite indicator 
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of ‘underlying health conditions’ that also included health-related behaviours. The additional 
MEDLINE search identified 121 unique studies and excluded 81 after screening of titles and abstracts. 
From the remaining 40 studies, two not already identified through other avenues were identified as 
potentially eligible for inclusion (12, 19). One of these was excluded because the age-adjusted estimates 
anticipated by the methods were not reported (19). 
Of the seven papers, five had been peer-reviewed (11-14, 16) while two were pre-prints not yet peer-
reviewed (10, 15). 
Characteristics of the included studies  
All the included studies were based in China during the initial stages of the pandemic. Three used data 
from Wuhan and the Hubei province (13, 15, 16), the epicentre of the Chinese outbreak, while the others 
focused on cases hospitalised outside Hubei, using either national samples (12) or records from a single 
tertiary hospital in another province (10, 11, 14). Sample sizes ranged from 171 (16) to 1,590 (12).  
Our review identified mostly studies with a cohort design, although only four studies accurately 
specified the study design. Convenience sampling seemed to be most common, however two studies 
only stated recruitment of consecutive patients (13, 15) and only two described excluded cases (13, 16). 
Sample construction in other studies was not explicit. Only one study specified inclusions and 
exclusions (13), albeit without comparing the 41% inclusions with the excluded cases. 
One study used a composite endpoint (death or admission to ICU or invasive ventilation) as the outcome 
(12). Three studies recorded death as the primary outcome (13, 15, 16), and three severe disease, 
including ICU admission (10, 11, 14). In one study, severity was not clearly defined but appeared to be 
based on a clinical evaluation of CT scans (14). In another study (15), severe and critical COVID-19 
illness was clearly defined based on the diagnostic and treatment guidelines of the National Health 
Committee of China.  
Comorbidities analysed were obesity, diabetes mellitus, hypertension and other circulatory disease 
(including cardiovascular and cerebrovascular disease), cancer, and chronic obstructive pulmonary 
disease (COPD). Additionally, two studies (11, 12) reported the association of one of the outcomes 
with the presence of any (or multiple) comorbid conditions rather than, or as well as, specific 
conditions. In five studies, information on comorbidities was collated from medical records but two of 
these did not specify the exact method. One study (13) reported details of a robust method of two 
researchers collecting data from medical records, followed by independent review and data entry by 
two analysts. Another study (16) reported using a structured form adapted from the 
WHO/International Severe Acute Respiratory and Emerging Infection Consortium case-record form 
to record clinical data, which two physicians then checked. One study included comorbidities self-
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reported on admission (12), and another measured weight and height on admission to calculate body 
mass index (BMI) (10).  
All included studies adjusted for age using multivariable regression models (Cox (n=3); logistic (n=3) 
or unspecified (n=1)). Most studies also adjusted for additional covariates, but the particular extra 
covariates differed across studies. In some studies (13, 14), details of the adjustment set were 
ambiguous, undermining confidence in any interpretation of the estimate. Additional covariates 
included sex, smoking, other comorbidities, and time from symptom onset to hospital admission. 
Importantly, four studies (11, 13, 15, 16) reported estimates of excess risk associated with comorbidity 
adjusted for clinically ascertained biomarkers (such as inflammatory response or organ function). In 
these four studies, full results are reported from multivariable models, and it appears (though is not 
stated explicitly) that comorbidities are considered potential confounders of associations between 
clinical predictors and disease progression. This is in contrast with the other three studies (10, 12, 14), 
which focused on estimation of the independent risk of experiencing a severe outcome according to 
comorbidity status, adjusted for age and other confounders.  
In the remainder of the narrative synthesis, we report first and in most detail on larger studies and those 
studies that directly attempted to estimate the age-adjusted effect of a comorbidity on any of the 
outcomes. Studies presenting models not appropriately designed for answering that particular research 
question are noted but considered less relevant.  
Comorbidity and severe/critical care COVID-19 outcomes 
Any comorbidity 
From the small number of studies published to date, there is preliminary evidence to indicate that 
hospitalised patients with any comorbidity are more likely to be admitted to ICU, require invasive 
ventilation, or die from COVID-19. In a nationwide study of 1,590 patients, Guan et al (12) examined 
the effect of ‘any comorbidity’ – as well as specific ones – and found evidence of a dose-response 
relationship. After adjustment for age and smoking status, patients with a single comorbidity had a 79% 
greater hazard of experiencing a severe outcome than patients with no comorbidities, while those with 
multiple comorbidities had a 159% increased hazard of severe outcome (HR=2.59, 95% CI: 1.61-4.17) 
(12). A second, smaller study of 249 patients in a Shanghai hospital estimated an age-adjusted odds 
ratio of similar magnitude for any comorbidity, but its wide 95% confidence interval included the null 
(0.50-6.75) (11). That study adjusted for clinical biomarkers, potentially making this an underestimate 
of the direct effect of comorbidity on the outcome.  
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Overweight and Obesity 
Cai et al (10) examined the relationship between overweight and obesity and progression to severe 
pneumonia in 387 hospitalised COVID-19 cases in Schenzen, a Chinese city outside the Hubei 
province. They found that, independent of age, obesity significantly increased the risk of developing 
severe pneumonia in COVID-19 patients, compared with patients of normal weight (OR=3.35, 95% CI: 
1.47-7.63). A dose-response relationship was observed, with overweight patients at intermediate risk 
(OR=1.78, 95% CI: 1.00-3.21). They also observed that the relationship was particularly pronounced 
in men (HR=5.40, 95% CI 1.93-15.09).  
Hypertension and CVD 
In their large nationwide study, Guan et al also examined a range of specific comorbidities and found 
that, after adjusting for age and smoking status, patients with hypertension at admission were 58% more 
likely to reach the composite endpoint (ICU admission, invasive ventilation, or death) than those 
without hypertension (HR 1.58, 95% CI: 1.07-2.32) (12).  
Similarly, Shi et al (14) found that the presence of hypertension at hospital admission was associated 
with 2.71 times the odds of severe disease (ICU admission), in a retrospective cohort of 487 patients in 
Zhejiang province of China, after adjusting for age, sex, and time from symptom onset to admission. 
Ambiguous reporting of the adjustment set for this analysis meant that this estimate should be 
interpreted with some caution. 
The only studies reporting hazard ratios for other cardiovascular and related comorbidities used 
multivariable models adjusted for clinical biomarkers that could relate to mediators of the pathway from 
prior comorbidity to COVID-19 severity (13, 16). Estimates are thus unlikely to represent the 
independent risk of severe outcomes associated with having these comorbidities. Their direction is 
consistent with an increased relative risk of death, but the confidence intervals are wide. 
Diabetes mellitus 
In studies examining diabetes mellitus as a comorbidity, the authors did not distinguish between Type 
1 and Type 2 diabetes. The large, nationwide study (12) found that hospitalised COVID-19 patients 
with diabetes had a 59% increased risk of the composite endpoint (ICU admission, invasive ventilation, 
or death) (HR 1.59, 95% CI: 1.03-2.45), after adjusting for age and smoking status. Zhang et al (15) in 
their study of 258 COVID-19 patients at a Wuhan hospital also found that those with diabetes were 
more likely to die in hospital, and point estimates were not materially different when adjusted for 
additional comorbidities as well as age (HR=2.84 cf. 2.80). After additionally adjusting for clinical 
biomarkers and other comorbidities, Shi and colleagues (13) reported no significant association between 
diabetes and mortality (HR=0.75; 95% CI: 0.38-1.50). 
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Cancer 
Guan et al (12) also examined cancer as a comorbidity, finding a substantially elevated risk of their 
composite endpoint amongst patients with cancer at admission to hospital. After adjusting for age and 
smoking status, patients with cancer had 3.5-fold the hazard of ICU admission, invasive ventilation, or 
death in hospital compared with patients without cancer (95% CI: 1.60-7.64). Just as for diabetes, Shi 
et al (13) reported no significant association between cancer and mortality, after additionally adjusting 
for clinical biomarkers and other comorbidities (HR=0.82; 95% CI: 0.18-3.65). 
COPD 
Regarding COPD, Guan et al found that hospitalised patients with COPD had 168% higher risk of 
reaching that study’s composite endpoint (ICU admission, invasive ventilation, or death) than patients 
without COPD (HR=2.68, 95% CI: 1.42-5.05), adjusted for age and smoking status. Again, Shi et al 
(13) reported no significant association between COPD and mortality after additionally adjusting for 
clinical biomarkers and other comorbidities (HR=0.39; 95% CI: 0.04-3.68). 
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Table 2. Extracted age-adjusted estimates (and 95% confidence intervals) of excess risk of progression to severe disease or death associated with 
comorbidities among hospitalised COVID-19 patients (published by 10 April 2020, all from China) 
Comorbidity  
 
(ref=comorbidity not present) 
Composite endpoint: 
ICU admission, invasive 
ventilation, or death 
Severe disease (including ICU 
admission) 
Death Samples sizes 
Any comorbidity     
One or more  OR=1.83 (0.50, 6.75) s, B (11) O  249 
One only  HR=1.79 (1.16, 2.77) sm (12) N   1,590 
Two or more HR=2.59 (1.61, 4.17) sm (12) N    1,590 
Obesity     
Overweight  OR=1.78 (1.00, 3.21) (10) O  387 
Obesity  OR=3.35 (1.47, 7.63) (10) O  387 
Cardiovascular and related     
Hypertension HR=1.58 (1.07, 2.32) sm (12) N OR=2.71 (1.32, 5.59) s,t (14) O  1,590,    487 respectively 
Coronary heart disease   OR=2.14 (0.26, 17.79) B (16) H 171 
Cardiovascular disease   HR=1.40 (0.65, 3.03) c, B (13) H 416 
Cerebrovascular disease   HR=1.71 (0.71, 4.09) c, B (13) H 416 
Diabetes mellitus HR=1.59 (1.03, 2.45) sm (12) N  HR=2.84 (1.01, 8.01) c (15) H 1,590,    258 
   HR=0.75 (0.38, 1.50) c, B (13) H 416 
Cancer HR=3.50 (1.60, 7.64) sm (12) N  HR=0.82 (0.18, 3.65) c, B (13) H 1,590,    416 
COPD HR=2.68 (1.42, 5.05) sm (12) N  HR=0.39 (0.04, 3.68) c, B (13) H 1,590,    416 
ICU = Intensive care unit                     
COPD = Chronic obstructive pulmonary disease                    
HR=hazard ratio                       
OR=odds ratio 
All estimates adjusted for age. Additionally adjusted for: 
sm = smoking       
s = sex      
t = time from symptom onset to admission        
c = other comorbidities        
B = clinical biomarkers (e.g. of inflammatory response or organ function) – potential intermediate markers of COVID-19 severity and not a reliable estimate of the comorbidity-associated 
relative risk of the outcome. 
Study population in China: N=nationwide, non-Hubei; H=Hubei province; O=other province 
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DISCUSSION 
Summary of the findings 
There is limited research on comorbidities as independent risk factors for severe COVID-19, but the 
emerging evidence base we identified supports the hypothesis that various underlying health conditions 
confer additional risk of severe disease and mortality among people hospitalised with COVID-19.  
Obesity, diabetes mellitus, hypertension, cancer, and COPD were all significantly associated with 
severe outcomes in the studies well designed to assess those associations  at least 50% higher than for 
people without the comorbidity. A dose-response relationship was reported for multiple comorbidities 
and for overweight and obesity. 
Comorbidity has previously been shown to be associated with elevated risk of worse clinical outcomes 
in other severe acute respiratory outbreaks such as SARS (severe acute respiratory syndrome), MERS 
(Middle East respiratory syndrome), and avian influenza (20-22). The findings of this review are 
consistent with the hypothesis that comorbidity also predisposes individuals to poorer outcomes in this 
current COVID-19 pandemic. Whilst the mechanisms remain poorly understood, there are numerous 
biologically plausible explanations. The pathogenesis of severe COVID-19 is thought to involve 
dysregulated proinflammatory immune response and subsequent multi-system damage (23). Many 
underlying conditions may leave affected individuals more vulnerable to the effects of this. Obesity, for 
example, tends to reduce lung function and dysregulate the immune system (24). Similarly, diabetes 
mellitus can impair immune function (25), as do many cancer treatments. Patients with pre-existing 
hypertension and other CVD may be at heightened risk of severe outcomes through various 
mechanisms, including therapeutic upregulation of ACE2 (the host receptor for SARS-CoV-2), and 
greater vulnerability to hyperinflammatory immune responses and cardiac complications that are 
common with severe COVID-19 (26, 27).   
Strengths and limitations in the evidence base  
The review includes two studies yet to undergo peer review, so these must be treated with caution, but 
it was deemed important to include these given the emerging pandemic and the need for timely evidence 
reviews.  
Our review identified mostly studies with a cohort design, appropriate for identifying independent risk 
factors for an outcome, although only four studies accurately specified the study design. Details of 
sampling and inclusion and exclusion criteria were scant in some studies, which undermines 
generalisability, and there may be a risk of selection bias when making inferences about the hospitalised 
COVID-19 population. Furthermore our review is limited to the hospitalised population of COVID-19 
cases. Our conclusions therefore only indicate the increased risk associated with comorbidities in 
hospitalised patients; we do not know what effect comorbidities have on the initial risk of being 
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admitted. Compared with many earlier case-series reports from China (Pennington et al, unpublished), 
the studies we identified had relatively large sample sizes, providing adequate statistical power to detect 
differences between groups of patients with and without comorbidities. 
Outcomes and definitions varied markedly between studies, compromising comparison of results and 
pooling estimates. Furthermore, understandably, patients in many studies had not yet reached their 
clinical endpoint and so the results are not complete. Many papers did not clearly specify the methods 
for data collection, particularly for recording comorbidities. In some, lack of rigour in comorbidity 
ascertainment might have led to misclassification and possible bias. Where case definition was not 
specified, comparing different studies was difficult. For example, some studies included cardiovascular 
disease or cerebrovascular disease as a comorbidity without specifying conditions included or excluded 
or specifying diagnostic criteria. Similarly, no study was clear about whether it distinguished between 
Type 1 and Type 2 diabetes mellitus, despite the two disease types having distinct aetiologies, age 
profiles (juvenile onset vs older ages), manifestations, and treatments, and therefore potentially not 
conferring equivalent risk with respect to COVID-19 severity.  
To analyse the association between the comorbidity and the outcome, all studies used multivariable 
regression analyses. Across studies, otherwise similar models differed considerably in adjusting for 
obvious confounders, such as sex or smoking, making comparison challenging. Furthermore, our 
inclusion and exclusion criteria retained studies reporting multivariable models that contained 
comorbidities as potential confounders of associations between clinical predictors and disease 
progression. In those studies, it is possible that the clinical predictors are intermediates on pathways 
through which comorbidity elevates the risk of death from COVID-19. If so, interpreting the 
hazard/odds ratios for comorbidity from these models would lead to a bias towards the null in any 
estimated effect of comorbidity, due to overadjustment by potential mediators.  
Overall the seven studies varied considerably both in the quality of the design and reporting. Whilst 
hasty research and publication are understandable in a global pandemic, rigour should not be 
compromised, as London & Kimmelman recently argued (28). Indeed, there is an ethical imperative to 
ensure that the conduct and reporting of research in a pandemic crisis maintains high standards of 
validity, reliability, and integrity to provide sufficiently robust evidence to inform clinical practice and 
public health policy. 
Strengths and limitations of the review  
This review has been rapid and timely, while also being as comprehensive as possible within those 
limits. A companion review provided forward citations, and our full-text MEDLINE search included 
pre-print archives as well as peer-reviewed literature, reflecting the fast-moving early stages of the 
pandemic and the increasing use of pre-print archives. While each early step used a single reviewer, 
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full-text screening used double screening. While we did not conduct a formal quality assessment, we 
have outlined here the major quality issues to consider in interpreting the results. 
The timing of the review and inevitable delay between research and publication meant that only studies 
from China met the criteria for inclusion. The Chinese study patients may be healthier because of 
different criteria for admission compared with other countries (e.g. the United Kingdom), where only 
relatively serious cases are hospitalised. The comorbidity profile of China also differs from that of many 
other parts of the world (29-31). Future studies must therefore examine comorbidities as risk factors for 
progression to severe COVID-19 and death in other settings globally. Updating this review to include 
such subsequent studies from outside China would be a valuable next step. Since the search completed 
in mid-April, a large study of hospitalised cases in the UK has emerged in pre-print (32). While it was 
thus not included in our analysis, it reports age-and-sex-adjusted estimates of mortality associated with 
a range of comorbidities that are consistent with those from the Chinese studies. They found higher in-
hospital mortality associated with obesity, cancer, chronic cardiac, pulmonary and kidney disease, and 
also dementia.  
Implications for future data collection and research 
COVID-19 studies to date have been produced very rapidly in a fast-moving pandemic. Reporting of 
methods would seem to have been adversely affected, and these preliminary studies are likely to feed 
into reviews and inform policy decisions. Transparent and detailed reporting of methods is required for 
accurate interpretation, particularly a clear rationale for model adjustment. Pre-agreed consistent 
methods of sample selection, description, and design (including variables to be measured and data 
collection tools) would facilitate more effective use and application of research efforts. It would also 
enable pooling of results from different locations and settings to provide high-quality evidence as 
quickly as possible. 
Implications for policy and practice 
People with various comorbidities appear, from the emerging evidence, to be at increased risk of severe 
disease progression and death after developing COVID-19. Elevated risk does not appear to be limited 
to specific comorbidities or organ systems. Rather, many of the most common chronic conditions confer 
an elevated risk of severe outcome, and there is also evidence that multimorbidity adds further risk. 
Given the relatively high prevalence of most of the comorbidities covered in this review, the 
implications of elevated risk among those affected are substantial. A recent study estimated that one in 
five individuals globally may be at increased risk of severe COVID-19 due to underlying conditions 
(33). This is likely to be an underestimate, as the study did not include obesity.   
Whether COVID-19 accelerates the underlying condition, or weakened underlying organs or immune 
response increase vulnerability to severe COVID-19, or both, remains an important area for further 
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research. Understanding the mechanisms involved is critical. Nevertheless, even without a full 
explication of the mechanisms, epidemiological evidence of an association between comorbidities and 
poor in-hospital outcomes still supports action to protect these groups and mitigate their elevated risk.   
In terms of primary prevention of COVID-19, the increased risk associated with many comorbidities 
supports strong, targeted measures to ‘shield’ people with comorbidities, and it suggests a need for 
public health campaigns to promote awareness of these elevated risks to enable people to protect 
themselves appropriately. If a vaccine becomes available, prioritisation of vaccination should be based 
on risk. In terms of secondary prevention of COVID-19, early COVID-19 detection must be promoted 
amongst those with comorbidities, to take advantage of any effective treatments that are developed. In 
terms of tertiary prevention, evidence of elevated risk of severe outcomes can also inform decisions 
around triage, patient management, treatment (prioritisation and care provision).  It may also point to a 
need for differential approaches to the care of recovered and recovering COVID-19 patients with 
comorbidities, due to their additional needs. In terms of resource allocation, the evidence of increased 
risk associated with comorbidities has implications for healthcare system demand in areas of high 
comorbidity prevalence. To address the greater burden of COVID-19 in communities with more pre-
existing conditions, greater resources will be needed in these communities. Current approaches, 
however, are not sufficiently taking into account the higher levels of need experienced by some 
communities due to comorbidities (34). This emerging evidence also has implications for the 
preparation for second and subsequent waves of community transmission. In addition to careful 
management of people with chronic conditions to minimise risk over the longer reach of this pandemic, 
it also highlights an added urgency for reducing the prevalence and incidence of comorbidities, through 
greater support for prevention efforts and addressing the wider determinants of health.    
Finally, the intersection of underlying comorbidity with socioeconomic disadvantage, geography, and 
demographic factors, especially ethnicity, may prove to be a potent mix that will lead to a widening of 
health inequalities. Recent data from the Office of National Statistics in the UK also showed that 
COVID-19 mortality rates are more than twice as high in the most deprived parts of England than in 
the least deprived areas (35). Deprivation increases the risk of poor health; higher levels of comorbidity 
in more disadvantaged groups is likely to be driving some of these COVID-19 inequalities, but social 
factors may also be playing a role (such as overcrowded housing, employment in essential occupations, 
particularly public-facing roles or others where physical distancing is not feasible, and greater reliance 
on public transport). Also in the UK, people from ethnic minority backgrounds are overrepresented 
among deaths from COVID-19 (36), with evidence that ethnicity is a risk factor independent of 
deprivation (37). Some of this disparity is likely to be due to the higher prevalence of common 
comorbidities in some of these groups. People with chronic health conditions, already disadvantaged 
and underrepresented in the workforce, are also more likely to be disadvantaged by the control 
measures. Without an effective vaccine or treatment many are likely to be isolated or shielded, and 
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therefore unable to conduct normal activities of daily living and working, for the foreseeable future. 
This has potential lasting implications for their financial, social, and mental wellbeing. Our review 
highlights that there are potentially people with chronic conditions across all age groups, such as 
younger people with Type 1 diabetes, conflated with older people. As far as is possible, people need 
support tailored to their need. Rather than being a ’great leveller’, this pandemic highlights the potential 
consequences of existing health inequalities and uneven distribution of underlying health conditions. 
Without concerted effort, the COVID-19 pandemic may lead to widening health inequalities between 
social, ethnic, and geographical groups. Responses to the pandemic must therefore prioritise and 
mitigate the unfair burden shouldered by disadvantaged and ethnic minority groups. 
Conclusion 
Building on evidence that people with comorbidities were overrepresented in hospitalised cases of 
COVID-19, this review compiles estimates from age-adjusted regression modelling across seven studies 
from China. It summarises for clinicians, policymakers, and academics the most robust evidence to date 
on this topic, to inform patient management and resource allocation for tackling the pandemic. Given 
the intersection of comorbidity with ethnicity and social disadvantage, these findings also have 
important implications for health inequalities. As the pandemic develops, further research is required 
to confirm these trends in other settings outside China and to explore the mechanisms by which various 
underlying health conditions increase risk of severe COVID-19.  
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